Momenta Pharmaceuticals Inc (MNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
56
About the Report
About the Report
Summary
Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The company's products include Glatopa; and Enoxaparin Sodium Injection. Its pipeline portfolio encompasses candidates to substitute Copaxone 40 mg/mL, Humira, and Orencia; an anti-FcRn antibody; selective immune-modulator of Fc receptors; hyper-sialylated IVIg as well as investigational candidate for the treatment of pancreatic cancer. The company utilizes its technology for developing generic versions of biosimilars, complex drugs, and potentially interchangeable biologics, and also in the discovery and development of therapeutics for various cancers and autoimmune indications. Momenta is headquartered in Cambridge, Massachusetts, the US.
Momenta Pharmaceuticals Inc (MNTA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Momenta Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Partnerships 12
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
Licensing Agreements 13
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Equity Offering 19
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc-Key Competitors 23
Momenta Pharmaceuticals Inc-Key Employees 24
Momenta Pharmaceuticals Inc-Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2018: Momenta Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 26
Aug 09, 2018: Momenta Pharmaceuticals announces second quarter 2018 financial results 28
May 08, 2018: Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 30
Feb 21, 2018: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 33
Nov 01, 2017: Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 02, 2017: Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 39
May 02, 2017: Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results 42
Feb 21, 2017: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 45
Corporate Communications 48
Oct 02, 2017: Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer 48
Jun 01, 2017: Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer 49
Legal and Regulatory 50
Mar 21, 2018: Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals and Sandoz 50
Government and Public Interest 51
Jan 06, 2017: Momenta Provides Year-End 2016 Corporate Update 51
Product News 53
05/17/2018: Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity 53
01/03/2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept) 54
Clinical Trials 55
Jan 05, 2018: Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List of Figure
List of Figures
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc, Key Competitors 23
Momenta Pharmaceuticals Inc, Key Employees 24
Momenta Pharmaceuticals Inc, Subsidiaries 25
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.